A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)

NCT05040568 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Colon Cancer
Resected Stage

Interventions

DRUG: Cetuximab
DRUG: Expanded CB-NK cells
DRUG: Fludarabine phosphate
DRUG: Cyclophosphamide

Sponsor

M.D. Anderson Cancer Center